Journal
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
Volume 34, Issue 4, Pages 372-374Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MEG.0000000000002203
Keywords
Crohn's disease; dual biologic therapy; multidrug refractory Crohn's
Categories
Ask authors/readers for more resources
The study demonstrates the efficacy of dual biologic therapy with vedolizumab and ustekinumab in treating highly refractory patients who have failed previous monotherapy.
There is a paucity of treatment options for patients who have failed multiple biologics. A drawback of biologic therapies is their selectivity in targeting a single pathway. We report the use of dual biologic therapy with vedolizumab and ustekinumab for three highly refractory patients who previously failed both of these medications as monotherapy. The dual biologic therapy led to the closure of a recto-vaginal fistula and restoration of continuity after takedown of a stoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available